Growth: head circumference (cm/week) · preterm or low birth weight infants
1 finding from 1 review
Extrauterine growth restriction at discharge · preterm or low birth weight infants
High showed no clear difference in extrauterine growth restriction at discharge compared with standard volume of fortified human milk or preterm formula (low certainty).
1 finding from 1 review
Necrotising enterocolitis · preterm or low birth weight infants
It is very uncertain whether high changes necrotising enterocolitis compared with standard volume of fortified human milk or preterm formula (very low certainty).
1 finding from 1 review
Weight gain · preterm or low birth weight infants
1 finding from 1 review
Linear growth (cm/week) · preterm or low birth weight infants
1 finding from 1 review
Growth: head circumference (cm/week) · preterm or low birth weight infants
1 finding from 1 review
Extrauterine growth restriction at discharge · preterm or low birth weight infants
1 finding from 1 review
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PEG interferon alpha‐2a · patients on HD with HCV infection
High showed no clear difference in PEG interferon alpha‐2a compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).
4 findings from 1 review
RR 5.66 [0.69, 46.31]
1 study · 81 participants
Low
RR 1.12 [0.4, 2.21]
1 study · 43 participants
Low
RR 1.19 [0.79, 1.78]
1 study · 81 participants
Low
Show 1 more finding
PEG interferon (alpha‐2b) · patients on HD with HCV infection
High showed no clear difference in PEG interferon alpha‐2b compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).
2 findings from 1 review
PEG interferon (combined) · patients on HD with HCV infection
High showed no clear difference in PEG interferon (combined) compared with low dose pegylated interferon alpha‐2a or alpha‐2b (moderate certainty).
3 findings from 1 review
RR 4.3 [0.76, 24.33]
2 studies · 97 participants
Moderate
RR 1.12 [0.4, 2.21]
1 study · 43 participants
Low
RR 1.05 [0.61, 1.83]
2 studies · 97 participants
Moderate
End‐of‐treatment response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with focal seizures
High probably leads to higher 50% reduction in seizure frequency (responders) compared with low stimulation (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with focal seizures
High showed no clear difference in withdrawals compared with low stimulation (low certainty).
1 finding from 1 review
Voice Alteration or Hoarseness · people with focal seizures
High probably leads to higher voice alteration or hoarseness compared with low stimulation (moderate certainty).
1 finding from 1 review
Cough · people with focal seizures
High showed no clear difference in cough compared with low stimulation (moderate certainty).
1 finding from 1 review
Dyspnea · people with focal seizures
High may leads to higher dyspnoea compared with low stimulation (low certainty).
1 finding from 1 review